Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA). This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results